Figure 2From: Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell linesCombination assays testing dasatinib with temozolomide at the specified ratios in (A) HT144 (ratio 1:1500), (B) Lox-IMVI (ratio 1:3000), (C) Malme-3M (ratio 1:800) and (D) Sk-Mel-28 (ratio 1:800) cells. Concentrations of temozolomide are represented as a ratio of the dasatinib concentration. Error bars represent the standard deviation of triplicate experiments.Back to article page